Noble Financial Has Positive Forecast for UNCY Q1 Earnings

Key Points

• Noble Financial raised its Q1 2026 EPS estimate for Unicycive to ($0.45) from ($0.47) and forecasts FY2026 EPS of $0.85, reflecting a notably more positive analyst outlook.
• Unicycive reported Q1 EPS of ($0.82) on March 30, missing analysts' consensus of ($0.46) by $0.36.
• Shares opened at $7.12 (up ~8.2%) with a market cap of ~$179.7M, and the stock has a Moderate Buy consensus and a mean price target of $34.33 amid ~40% institutional ownership and recent stakes from major funds.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a report issued on Tuesday, March 31st. Noble Financial analyst R. Leboyer now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Noble Financial also issued estimates for Unicycive Therapeutics' Q2 2026 earnings at ($0.52) EPS, Q4 2026 earnings at $0.87 EPS and FY2026 earnings at $0.85 EPS.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.36).

Other equities research analysts also recently issued research reports about the company. Guggenheim reissued a "buy" rating on shares of Unicycive Therapeutics in a report on Tuesday, December 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Finally, Westpark Capital started coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They set a "buy" rating on the stock. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $34.33.

Unicycive Therapeutics Trading Up 8.2%

Shares of Unicycive Therapeutics stock opened at $7.12 on Thursday. The firm has a market capitalization of $179.71 million, a PE ratio of -3.28 and a beta of 1.81. The firm's 50 day moving average is $6.67 and its 200 day moving average is $5.78. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $11.00.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors have recently modified their holdings of the company. Millennium Management LLC bought a new stake in Unicycive Therapeutics during the 4th quarter valued at $5,856,000. Vivo Capital LLC increased its position in shares of Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company's stock worth $7,804,000 after acquiring an additional 652,901 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of Unicycive Therapeutics in the 4th quarter worth about $1,154,000. Squarepoint Ops LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $512,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Unicycive Therapeutics in the 4th quarter valued at about $451,000. 40.42% of the stock is owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.